Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
PTC Therapeutics
PTC Therapeutics is a commercial-stage rare disease biotech developing small-molecule splicing modifiers and gene therapies for Duchenne muscular dystrophy, Friedreich ataxia, and other genetic disorders. Recent expansion into Fabry disease via the ST-920 acquisition.
Company Info
Recent News
PTC bets $211M on ‘special opportunity’ to enter Fabry market
PTC bets $211M on ‘special opportunity’ to enter Fabry market
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
/PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it was selected as the winning bidder to acquire ST-920 – a BLA-stage one-time...
PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy
Sangamo Therapeutics filed for Chapter 11 bankruptcy in June after its search for strategic alternatives failed to find a path forward for the company. PTC Therapeutics’ auction win brings a Sangamo gene therapy candidate for Fabry disease, a rare inherited disorder with few treatment options.